Clinical Trial Update: Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease [Phase 1, Phase 2]

View source ↗

Summary

A multicenter study evaluating delayed-release 6-mercaptopurine for Crohn's disease (Phase 1/Phase 2) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Delayed Release 6-mercaptopurine (6-mercaptopurine)

Snippet

Sponsor: Teva GTC | Conditions: Crohn's Disease | Phase 1, Phase 2 | Status: TERMINATED